Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab as alternative to radiochemotherapy in dMMR uterine cancer
2022-003922-27Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in uterine cancer, sponsored by University Medical Center Groningen. Primary endpoint: Major pathologic response rate. Started Feb 2024; status: active.
02
Drugs
03
Conditions
uterine cancer
Beyond the preview
Go deeper on 2022-003922-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003922-27.